168
Participants
Start Date
June 29, 2021
Primary Completion Date
December 31, 2025
Study Completion Date
December 31, 2026
TJ033721 (givastomig)
Tetravalent IgG(H)-scFv fusion-type of bi-specific antibody (BsAb)
TJ033721 (givastomig) , nivolumab, chemotherapy
Tetravalent IgG(H)-scFv fusion-type of bi-specific antibody (BsAb), nivolumab, chemotherapy
RECRUITING
NYU Langone, New York
RECRUITING
Memorial Sloan Kettering Cancer Center, New York
COMPLETED
Carolina BioOncology Institute, Huntersville
RECRUITING
Vanderbilt-Ingram Cancer Center, Nashville
NOT_YET_RECRUITING
Henan Cancer Hospital, Zhengzhou
COMPLETED
Horizon Oncology Research, LLC., Layfayette
RECRUITING
UW Carbone Cancer Center, Madison
COMPLETED
Mary Crowley Cancer Research, Dallas
RECRUITING
UCHealth Cancer Care - Anschutz Medical Campus, Aurora
RECRUITING
Stern Center for Cancer Clinical Trials and Research, Orange
RECRUITING
Beijing Cancer Hospital, Beijing
RECRUITING
The First Hospital of China Medical University, Shenyang
NOT_YET_RECRUITING
HARBIN Medical University Cancer Hospital, Harbin
RECRUITING
Zhongshan Hospital, Fudan University, Shanghai
NOT_YET_RECRUITING
The Second Hospital of Anhui Medical University, Hefei
RECRUITING
Tianjin Medical University Cancer Institute and Hospital, Tianjin
RECRUITING
Hubei Cancer Hospital, Wuhan
RECRUITING
Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou
RECRUITING
Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hongzhou
RECRUITING
Mass General Hospital, Boston
ACTIVE_NOT_RECRUITING
Rutgers Cancer Institute of New Jersey, New Brunswick
Lead Sponsor
Collaborators (1)
Bristol-Myers Squibb
INDUSTRY
I-Mab Biopharma US Limited
INDUSTRY